Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NIH-funded Institutional Training Programs in Colleges and Schools of Pharmacy.

American journal of pharmaceutical education·2026
Same author

Strategies to Address Communication Vulnerability in Adult Intensive Care Units Through Practice, Environment, and Policy Modifications.

Journal of nursing care quality·2026
Same author

Tegmental kappa-opioid receptor neurons modulate opioid withdrawal via the periaqueductal gray.

Brain : a journal of neurology·2026
Same author

Scoping review of patient and family engagement interventions in diagnosis: a paradox of too much, yet so little.

BMJ quality & safety·2025
Same author

Barriers to and facilitators for implementing a Care Partner program for adult patients with persistent critical illness.

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2025
Same author

Reported contributors to communication vulnerability for adult patients in critical care.

Intensive & critical care nursing·2025

Related Experiment Video

Updated: Jun 19, 2026

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
04:24

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease

Published on: September 5, 2025

Changing winds: practice implications of acetaminophen regulations.

Andrew L Rogalski1, Kelly M Smith

  • 1University of Kentucky Healthcare, Lexington, Kentucky 40536, USA.

Orthopedics
|October 15, 2009
PubMed
Summary

The FDA advisory committee recommended changes to reduce acetaminophen liver injury. These proposals may significantly alter acetaminophen products, impacting patient safety and orthopedic care.

Area of Science:

  • Pharmacovigilance
  • Hepatology
  • Regulatory Science

Background:

  • Acetaminophen (APAP) is a common analgesic and antipyretic.
  • Acetaminophen-induced liver injury (AILI) remains a significant public health concern.
  • Previous FDA actions have aimed to mitigate AILI risks.

Purpose of the Study:

  • To review the FDA advisory committee meeting on AILI prevention.
  • To summarize proposed recommendations for reducing AILI incidence.
  • To discuss implications for orthopedic practitioners.

Main Methods:

  • Convening of a joint FDA advisory committee meeting in June 2009.
  • Review of existing data and risk factors for AILI.
  • Deliberation and voting on proposed risk-reduction strategies.

Related Experiment Videos

Last Updated: Jun 19, 2026

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
04:24

Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease

Published on: September 5, 2025

Main Results:

  • The committee voted in favor of 7 out of 9 proposed recommendations.
  • Supported recommendations aim to reduce the incidence of acetaminophen-induced liver injury.
  • Potential for significant changes to both OTC and prescription acetaminophen products.

Conclusions:

  • The committee's recommendations represent a proactive approach to AILI prevention.
  • These changes could impact the formulation, labeling, and accessibility of acetaminophen.
  • Orthopedic practitioners should be aware of these evolving regulatory actions and their clinical relevance.